NASDAQ: GRDXGridai Technologies Corp Stock
$3.92-0.04 (-1.01%)
Updated Jan 16, 2026
GRDX Price
$3.92
Fair Value Price
$0.01
Market Cap
$13.18M
52 Week Low
$0.97
52 Week High
$5.84
P/E
-0.32x
P/B
0.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.03
Operating Cash Flow
-$2M
Beta
0.58
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GRDX Overview
GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GRDX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GRDX
Ranked#159 of 490
Ranked#159 of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.44 | A | |
| $5.42 | A | |
| $14.85 | A |
Be the first to know about important GRDX news, forecast changes, insider trades & much more!
GRDX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GRDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRDX ($3.92) is overvalued by 58,591.23% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GRDX ($3.92) is not significantly undervalued (58,591.23%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GRDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GRDX due diligence checks available for Premium users.
Valuation
GRDX fair value
Fair Value of GRDX stock based on Discounted Cash Flow (DCF)
Price
$3.92
Fair Value
$0.01
Overvalued by
58,591.23%
GRDX ($3.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GRDX ($3.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GRDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GRDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.32x
Industry
172.38x
Market
46.6x
GRDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
5.49x
GRDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRDX's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.2M
Profit Margin
0%
GRDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$135.4M
Liabilities
$45.8M
Debt to equity
2.03
GRDX's short-term assets ($87.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRDX's short-term assets ($87.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GRDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$855.7k
Investing
$336.4k
Financing
$3.0M
GRDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRDX vs Biotech Stocks
Gridai Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.